$VERA: a commercial-stage kidney franchise on one differentiated molecule
$VERA · Vera Therapeutics, Inc · by Thomas Bouman ·
covered since
bullishRating
$70.00Price target · 12M
$36.05Written at
5Notes
Vera turned atacicept into the first approved dual BAFF/APRIL inhibitor for IgA nephropathy, with a clean label and an at-home autoinjector. Consensus peak sales sit roughly at the current enterprise value, which leaves the franchise beyond IgAN effectively unpriced.
The Thesis (The Story)
The approval
Vera became a commercial-stage company on July 7, when the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for primary IgA nephropathy (IgAN), a kidney disease where antibodies build up in the kidneys and slowly destroy their filtering function. TRUTAKNA is the first and only approved drug that blocks two related immune signals, BAFF and APRIL, at once. Both drive the production of the harmful antibodies behind this disease, so blocking both instead of just one is meant to hit the root cause more completely than earlier single-target drugs.
The mechanism and the data
Atacicept works by mimicking a natural human protein (a TACI-Fc fusion, essentially a decoy receptor that soaks up BAFF and APRIL before they can act). That's a familiar, well-understood mechanism, patients didn't develop resistance to it in trials, and its safety profile looked comparable to placebo across the full study program. Approval was based on proteinuria, the amount of protein leaking into urine, a marker doctors use to track kidney damage: atacicept cut proteinuria by 46% from baseline and by 42% more than placebo at 36 weeks. It's delivered as a once-weekly injection patients can give themselves at home. Vera licensed the molecule from Merck KGaA back when IgAN had zero approved treatments. It now launches into a market with several, which cuts both ways: more competition, but also proof the disease is now considered treatable and worth targeting.
Why the opportunity is bigger than the current label
The dual-mechanism approach puts Vera ahead of the other companies chasing the same combined target, Vertex's povetacicept is the closest rival and is still behind in development. Beyond the mechanism, the actual pool of treatable patients is expanding. Updated 2025 treatment guidelines (KDIGO) now recommend biopsying patients at a lower protein-leakage threshold than before, and lowered the treatment goal itself, meaning more patients who previously would have stayed on older, non-specific blood pressure and kidney drugs now qualify for active treatment. Outside the US, Europe adds tens of thousands more patients on top of the roughly 160,000 in the US, and Asia carries the largest share of the disease globally. On top of IgAN itself, the same drug and safety data are being positioned for two related kidney diseases, membranous nephropathy and FSGS, extending the potential franchise well past the current approval.
Against all of that, sell-side estimates put worldwide peak sales near $2.1B, versus an enterprise value around $2.4B, close to only pricing in the single, conservative base case.
🐂 Bull Case
First-in-class among dual-target inhibitors, and the 2025 guideline update is expanding the treated population rather than just splitting an existing one
Compliance ran around 93% in the long-term extension study, and a future move to monthly (instead of weekly) dosing would remove the main objection doctors currently raise
Roughly half of surveyed prescribers said they'd consider combining this drug with another newer drug class (an endothelin receptor antagonist), growing the total treated pool rather than fighting over the same patients
Expansion into membranous nephropathy and FSGS is real optionality that isn't reflected in the current price
🐻 Bear Case
The approval is "accelerated," meaning it's based on a proxy marker (proteinuria) rather than direct proof of long-term kidney function. A weak confirmatory result on the follow-up measure (eGFR, a direct measure of kidney function) threatens the approval itself, not just future growth
Two competitors already have confirmatory kidney-function data in hand and are moving toward standard, non-accelerated approval while Vera still has to deliver that data
Insurance friction is a real barrier across this entire drug class: prior authorizations, step-therapy requirements, and specific protein-leakage thresholds before coverage kicks in
Weekly dosing is a real disadvantage against competitors until monthly dosing data exists
Launching commercially is expensive, and Vera is going up against far larger competitors, with real dilution risk if early sales disappoint
Conclusion
The approval itself was the setup, not the payoff. What happens next is largely regulatory: converting accelerated approval into full approval on the Q3 kidney-function data, then filing for the label expansion that would lock that in. After that, this becomes a story about commercial execution, and eventually, franchise expansion into the two adjacent kidney diseases.
The risk worth watching is that being first among dual-target inhibitors matters less than actually executing against larger, better-resourced competitors already in the market.
Update notes & developments
VERA: ORIGIN 3 final data — all endpoints met, +5.0 eGFR treatment effect
Development · · written at $34.05
ORIGIN 3 final analysis hit every prespecified endpoint: annualized eGFR treatment effect of +5.0 (vs Otsuka's own +4.5 on the identical metric), plus a 0-vs-8 composite hard-outcome result.
What happened
Vera announced the final efficacy analysis of ORIGIN 3 (n=428) in IgA nephropathy. All prespecified endpoints were met.
The numbers
Annualized eGFR slope through 104 weeks: -0.6 (TRUTAKNA) vs -5.6 (placebo). Treatment effect +5.0, p<0.0001.
Mean eGFR change from baseline at 52 weeks: Treatment effect +5.6, p<0.0001.
Composite kidney disease progression event through 104 weeks: 11 (drug) vs 38 (placebo). HR 0.24 (76% risk reduction).
Dialysis ≥30 days, transplant, or death through 104 weeks: 0 (drug) vs 8 (placebo).
Safety: Generally comparable to placebo, consistent with prior ORIGIN data. No unusual infections or dangerous drops in antibody levels.
Worth highlighting on replication: -0.6 on the drug arm is the exact same annualized slope the Phase 2b study produced. A 428-patient, placebo-randomized Phase 3 landing on the exact figure a much smaller earlier study suggested isn't just directional consistency. It shows the drug works very predictably.
Framed against kidney health guidelines, the drug-arm decline here sits in the range associated with normal, age-related kidney loss rather than disease-driven decline. That is the practical meaning of "stabilization" underneath the slope number.
The Otsuka comparison
This was the number the market was waiting on. Otsuka's VISIONARY final data on the same metric (annualized eGFR slope, 24 months): +0.3 (sibeprenlimab) vs -4.2 (placebo), treatment effect +4.5, p<0.0001.
TRUTAKNA's +5.0 is the larger number on the identical metric and timepoint structure. However, the shape is different: Otsuka's drug arm shows an absolute gain in kidney function (+0.3), while TRUTAKNA's drug arm still shows a slight absolute decline (-0.6), just a much slower one than placebo. So Otsuka wins on absolute value, while TRUTAKNA wins on treatment effect vs. placebo. Both views are valid.
One thing Otsuka hasn't reported in their releases: a hard-outcome comparison anywhere near 0 vs 8 on dialysis, transplant, or death. That composite result does not have a direct Otsuka equivalent to benchmark against.
Standard caveat applies: this is a cross-trial comparison, not a head-to-head study. Different populations, different sites, and different timelines.
Commercial
350+ patient start forms in the first ten weeks of the accelerated-approval launch, and that pace held despite the drug not being available in the channel until week three, plus an August launch window that typically sees slower uptake. Some desks are benchmarking that weekly pace against Otsuka's early numbers and calling it comparable; I haven't independently verified Otsuka's exact figure so I'm not putting a number on that comparison here. If true, the interesting part isn't the raw pace, but what TRUTAKNA's launch was working against while keeping it.
For scale, at TRUTAKNA's list price of ~$425K/year, roughly 2,400 patients on drug gets you to a ~$1B annualized revenue run-rate. That's a patient count a real IgAN market should easily support if uptake continues, a useful reference point for sizing what these early start-form numbers could eventually mean.
Next step
sBLA for full approval planned Q4 2026. Detailed results to be presented at an upcoming scientific congress.
$VERA: FDA review docs show early eGFR data comparable to Otsuka's Voyxact
Development · · written at $28.89
FDA review documents for Trutakna disclosed interim eGFR slope data at week 52/72 that looks broadly in line with Otsuka's Voyxact at week 104. Small interim cohort, wide confidence intervals, but it narrows one of the bigger open questions ahead of the Q3 ORIGIN 3 readout.
What this note is about
FDA review documents for Trutakna (atacicept), released as part of the accelerated approval package, included interim eGFR slope data that hadn't been public before. This matters because the confirmatory ORIGIN 3 eGFR readout, due Q3 2026, is the single biggest open question behind the accelerated approval, whether atacicept protects kidney function as well as it reduces proteinuria.
For comparison, Otsuka's Voyxact reported a final placebo-adjusted slope of +4.7 (95% CI 3.8-5.6) at week 104 on the full 510-patient population
Trutakna's drug-arm slope moved from -0.3 at week 52 to +0.9 at week 72 in the interim analysis, in the same range as Voyxact's +1.3 at week 104
ADA (anti-drug antibody) positivity was reported at 43%, with no apparent impact on efficacy in the review documents. Neutralizing ADA rates are to be assessed under post-marketing commitments
Why this needs a caveat
This is small-n interim data (roughly 45 patients per arm at week 52, closer to 15 per arm at week 72), not the final ORIGIN 3 analysis. The confidence intervals are wide, and this is a cross-trial comparison against Voyxact's separate, larger, later-timepoint dataset, not a head-to-head. This is hypothesis-generating, not confirmatory. It reduces one specific risk, that the interim trend points meaningfully worse than Otsuka's, without derisking the full Q3 readout.
What this means
Ahead of Q3, the market's main downside scenario has been a visibly worse eGFR trajectory than Voyxact. These review documents make that specific scenario look less likely, the interim direction and magnitude are broadly comparable, not obviously inferior. It doesn't change my target or rating on its own, this is still an open catalyst, but it does narrow the range of plausible bad outcomes going into ORIGIN 3.
$VERA: Otsuka's clean 2yr eGFR print raises the bar right before Vera's own readout
Development · · written at $29.95
Otsuka posted VISIONARY 2-year eGFR data (+4.5 treatment effect, p<0.0001) — a strong class-level signal for APRIL inhibition, but it also sets the bar atacicept's own ORIGIN 3 readout now has to clear.
What happened
Otsuka reported full 2-year VISIONARY eGFR data on Aug 4 for sibeprenlimab (Voyxact): annualized slope +0.3 vs -4.2 with placebo, a treatment effect of +4.5 mL/min/1.73m2/yr, p<0.0001. Clean result, tight confidence interval, meets the KDIGO threshold for physiologic decline. This is a strong class level confirmation that APRIL inhibition works on a hard kidney function endpoint, not just on proteinuria as a surrogate. That is a genuine tailwind for the mechanism behind atacicept too, since it shares the APRIL target.
Why it raises the bar for Vera
It sets a much higher comparison bar for Vera's own ORIGIN 3 eGFR readout, still expected in Q3 with no fixed date yet. Every future atacicept eGFR result will now be read against Otsuka's +4.5 benchmark, so a merely positive outcome may not be received as a win even if it is technically successful. Otsuka is also ahead in the race to traditional approval: their rolling sBLA has been in progress since June, while Vera's own sBLA filing is not planned until Q4. Atacicept remains second to market with weekly dosing versus monthly for both sibeprenlimab and povetacicept, and Vertex's povetacicept PDUFA on Nov 30 is closing the launch order gap faster than earlier assumed.
Why the market is big enough regardless
The IgAN market itself is large and structurally underpenetrated. Updated KDIGO guidance is pulling more patients into active treatment earlier in the disease course, and current US estimates of roughly 100k treated patients likely understate the real opportunity once Europe and Asia are included, where IgAN prevalence is highest globally. Atacicept's own earlier open label extension data already trended toward stable eGFR over 96 weeks, even if uncontrolled, which is a supportive signal ahead of its own confirmatory readout. A modest fraction of the expanded treatable population is enough to support a meaningful revenue base for atacicept even without winning the largest share of the class.
Bottom line
The Otsuka data is a net positive for the IgAN class as a whole and validates APRIL inhibition on the endpoint that actually matters for full approval. The open question is no longer whether the mechanism works, but whether atacicept's own data clears the new, higher bar Otsuka just set, in a market large enough that being second or third best still leaves real room to build a franchise.
$VERA: the eGFR readout is the re-rate, not the approval
Update note · · written at $36.05
Accelerated approval came on proteinuria, a surrogate. The confirmatory eGFR readout proves whether atacicept actually slows kidney decline and converts the approval into a full one. The market gave the approval +5% and moved on, so this event isn't priced.
What this readout is
Vera's July approval was accelerated, granted on proteinuria reduction. Proteinuria is a surrogate: it correlates with kidney damage and it reads out in months rather than years, which is why regulators accept it. It is not the thing itself.
The thing itself is eGFR, how well the kidney is actually filtering. In IgA nephropathy the endpoint that matters over a patient's life is how fast that number falls. A drug that lowers protein in the urine without changing that slope has not really treated the disease.
ORIGIN 3's confirmatory eGFR analysis answers that for atacicept, and it is what converts accelerated approval into full approval via the Q4 sBLA.
Why it's arriving early
The analysis was pulled forward after an FDA alignment in June. That detail is worth sitting with: a company does not accelerate its own confirmatory analysis unless it likes what is coming, because a soft result arriving sooner is worse than a soft result arriving later. Management has pointed to the effect size seen in Phase 2b, where atacicept stabilised kidney function in patients expected to decline. Behavioural signal, not evidence, but worth weighing.
The bar is already set
Vera is not reading into a vacuum. Otsuka's sibeprenlimab posted +0.7 mL/min/1.73m² versus −4.8 for placebo at 12 months, followed by positive two-year VISIONARY data. Novartis' iptacopan showed a 49.3% slowing of eGFR slope decline over two years. Both are moving toward traditional approval.
Cross-trial comparison is limited by different populations and designs, so this is directional rather than a scoreboard. But prescribers will make the comparison regardless of whether it is methodologically clean.
🐂 What a good print looks like
A kidney-function benefit competitive with or better than those numbers, putting atacicept on outcome data rather than a surrogate.
Full approval secured through the Q4 sBLA, removing the conditional element from the label.
Payer friction and the weekly-dosing objection become commercial problems to solve rather than reasons to stay out.
Read-through to membranous nephropathy and FSGS on the same mechanism.
🐻 What would break it
A soft or missed result. This does not just cap upside: a failed confirmatory endpoint threatens the accelerated approval itself.
An in-line result. Full approval still follows, but atacicept becomes one of several drugs with comparable data, decided on dosing convenience and payer access, where Vera is not obviously advantaged today.
A timing slip past Q3, which compresses the sBLA and gives competitors more runway.
Subgroup noise: a headline that works but weakens on closer reading.
Conclusion & My Position
The approval moved the stock roughly 5% and then it went flat, which tells you the proteinuria story was already understood. That leaves Vera sitting still ahead of the event that decides the franchise, rather than exhausted after a run-up.
What I'm underwriting is not just a positive result but a competitive one. That spread, between in-line and strong, is the trade, and it resolves this quarter.
Position at publication: long VERA, held through approval, no change planned into the readout.